FDA Eases Regulation on AI-Enabled Wearables to Boost Adoption
The FDA aims to encourage innovation and deployment of AI-enabled medical devices by reducing oversight, signaling a shift in regulatory approach toward digital health technology.
FDA Policy Update on Digital Health Devices
The U.S. Food and Drug Administration (FDA) has declared plans to significantly ease oversight of digital health products, focusing on AI-enabled devices and wearables. This policy shift is intended to deregulate aspects of AI technologies to promote their broader application in healthcare.
- The deregulation aims to accelerate AI integration in medical devices.
- It may reduce regulatory burdens that previously slowed device approvals.
- The move could increase availability of innovative digital health tools for clinicians and patients.
This development reflects an evolving regulatory stance aiming to balance innovation with safety in medical technology.
Source: STAT News
Join the BioIntel newsletter
Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy—delivered to your inbox.